Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LSS | P48449 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 7/20 | 0.49 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.46 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23747650 | 1.00 | TP53 (0.62) | TP53CHRM1HTR2AMCHR1RAB9A | |
| SCHEMBL26101615 | 1.00 | TP53 (0.62) | TP53CHRM1HTR2AMCHR1RAB9A | |
| SCHEMBL23747367 | 0.94 | CHRM1 (0.64) | TP53CHRM1HTR2AMCHR1RAB9A | |
| SCHEMBL23747570 | 0.92 | CHRM1 (0.61) | TP53CHRM1HTR2AMCHR1RAB9A | |
| SCHEMBL26098578 | 0.89 | SMN1; SMN2 (0.55) | TP53MCHR1RAB9ANPC1POLB | |
| SCHEMBL23747602 | 0.89 | SMN1; SMN2 (0.55) | TP53MCHR1RAB9ANPC1POLB | |
| SCHEMBL23747829 | 0.89 | SMN1; SMN2 (0.55) | TP53MCHR1RAB9ANPC1POLB | |
| SCHEMBL23747831 | 0.81 | SMN1; SMN2 (0.60) | MCHR1RAB9ANPC1POLBNAMPT | |
| SCHEMBL23747743 | 0.81 | CHRM1 (0.67) | TP53CHRM1HTR2AMCHR1RAB9A | |
| SCHEMBL26547780 | 0.79 | CHRM1 (0.64) | TP53CHRM1HTR2AMCHR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | TP53 4738/4885CHRM1 1155/4885HTR2A 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.